Back

How potassium binders can enable RAASi therapy in heart failure.

27 August 2022 (13:05 - 13:20)
Organised by:
Congress Presentation Part of: Clinical case discussion: the value of optimising RAAS inhibition and preserving normokalemia in heart failure Heart Failure with Reduced Ejection Fraction (HFrEF) Open Access ESC Congress 2022

About the speaker

Photo
Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)

4 More presentations in this session

Presentation thumbnail
Clinical case presentation of a patient with heart failure.
Professor P. Van Der Meer (Groningen, NL)
Slides Video
Presentation thumbnail
The importance of optimal RAASi therapy in heart failure.
Professor D. Atar (Oslo, NO)
Slides Video
Presentation thumbnail
Practical guidance on use of potassium binders in the management of hyperkalemia in heart failure.
Doctor C. Bonanad Lozano (Valencia, ES)
Slides Video
Presentation thumbnail
Panel discussion.
Professor P. Van Der Meer (Groningen, NL)
Slides Video

Access the full session

Session thumbnail
Clinical case discussion: the value of optimising RAAS inhibition and preserving normokalemia in heart failure
Video

The Event

Event poster

ESC Congress 2022

27 August 2022 13:05 CET
You may be interested in
thumbnail
Congress Presentation
Clinical choices in tackling the risk of hyperkalaemia
thumbnail
Congress Presentation
Challenges of managing hyperkalaemia in HF patients with CKD while maintaining RAAS inhibitor therapy
thumbnail
Congress Presentation
1st case presentation: chronic or recurrent hyperkalemia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources